STRATA Skin Sciences announces clinical study showing TheraClear X reduces acne lesions by ≥50% after three treatments

STRATA Skin Sciences, Inc.

Study in Journal of Cosmetic and Laser Therapy (July 11, 2024) evaluated 7 female patients with mild-moderate acne.
All patients achieved ≥50% clearance of comedones, pustules, and inflammatory lesions after three treatments.
Side effects were mild and transient: erythema, bruising, superficial erosions, temporary pigmentation changes (48-72 hours).
TheraClear X is FDA-cleared as a noninvasive, in-office treatment for mild-to-moderate acne, combining vacuum and broadband light.
President and CEO Dr. Dolev Rafaeli cited photopneumatic therapy as a viable alternative for patients resistant to traditional treatments.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.